查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593744

类风湿性关节炎药物市场评估：按分子类型、药物类别、销售管道和地区划分的机会和预测（2017-2031）

Rheumatoid Arthritis Therapeutics Market Assessment, By Type of Molecule, By Drug Class, By Sales Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 239 Pages | 商品交期: 3-5个工作天内

价格

全球类风湿性关节炎药物市场规模预计将从 2023 年的 300.5 亿美元增长到 2031 年的 463.9 亿美元，预测期内复合年增长率为 5.58%。

类风湿性关节炎病例数量的增加、为更好地瞭解该疾病而开展的研究活动的增加以及全球各个监管机构批准的增加推动了市场的增长。人口老化的加剧也导致类风湿性关节炎病例增加。世界卫生组织（WHO）估计，到2030年，世界上六分之一的人将超过60岁，到2050年，大约21亿人将超过60岁。类风湿性关节炎影响滑膜关节，引起炎症，导致长期功能丧失和关节损伤。

此外，各个监管机构越来越多地批准类风湿关节炎药物，这将确保世界各地的患者能够获得所需的药物。

此外，对具有相似治疗效果的生物相似药的日益接受度也正在扩大全球类风湿关节炎药物市场的规模。领先的製药公司正在积极投资新生物相似药和生物製品的审批和开发，对市场成长产生正面影响。此外，世界各地的各种研究机构和公司正在积极投资开发比传统疗法副作用更少的新疗法。我们也透过分享各自的资源和专业知识来进行联合研究。

本报告调查了全球类风湿性关节炎治疗药物市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析、行业结构以及影响因素的市场成长分析、案例。

目录

第一章专案范围与定义

第二章研究方法

第 3 章执行摘要

第四章全球类风湿性关节炎药物市场展望

  • 市场规模分析与预测
  • 市占率分析/预测
    • 依分子型
    • 依药物类别
    • 按销售管道
    • 按地区
    • 按公司划分的市占率分析
  • 市场地图分析

第五章北美类风湿性关节炎药物市场展望

  • 市场规模分析与预测
  • 市占率分析/预测
  • 国家市场评估
    • 美国
    • 加拿大
    • 墨西哥

第六章欧洲类风湿关节炎药物市场展望

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第七章亚太类风湿关节炎药物市场展望

  • 印度
  • 中国
  • 日本
  • 澳大利亚
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第八章南美类风湿关节炎药物市场展望

  • 巴西
  • 阿根廷

第九章中东与非洲类风湿关节炎药物市场展望

  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第10章供需分析

第11章价值链分析

第十二章波特五力分析

第 13 章 PESTLE 分析

第14章价格分析

第 15 章市场动态

  • 市场驱动因素
  • 市场课题

第16章市场趋势与发展

第 17 章法律与监管架构/创新

  • 临床试验
  • 监理机关的核准

第十八章专利状况

第 19 章案例研究

第20章竞争态势

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名的公司的 SWOT 分析
  • 前10名企业状况
    • AbbVie Inc.
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc.
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Eli Lilly and Company
    • Johnson & Johnson Services, Inc.

第 21 章策略建议

第22章关于我们公司/免责声明

Product Code: MX12256

Global rheumatoid arthritis therapeutics market is projected to witness a CAGR of 5.58% during the forecast period 2024-2031, growing from USD 30.05 billion in 2023 to USD 46.39 billion in 2031. The market's growth is bolstered by the rising cases of rheumatoid arthritis, increasing research activities to improve the understanding of the disease, and growing approvals from different regulatory bodies across the globe. The expansion of the geriatric population is also augmenting the cases of rheumatoid arthritis. As per the World Health Organization (WHO) estimates, one in six people across the globe will be sixty or older by 2030, and by 2050, approximately 2.1 billion people will be sixty or older. Rheumatoid arthritis affects the synovial joints and causes inflammation that can result in loss of function and joint damage over a period of time.

Additionally, increasing the provision of approvals for drugs for rheumatoid arthritis by different regulatory bodies ensures that patients worldwide have access to the necessary medication. In October 2024, Alfasigma S.p.A. received the green light for the commercialization of Jyseleca, a JAK1 drug used for ulcerative colitis and rheumatoid arthritis, following the approval received from the European Medicines Agency. The transfer of marketing authorization for the drug in the European Union was completed after the company purchased the medication for USD 186 million.

Moreover, the growing acceptance of biosimilars, the economically efficient alternatives to biologic drugs with similar therapeutic effects, bolsters the global rheumatoid arthritis therapeutics market size. Major pharmaceutical companies actively invest in approving and developing new biosimilars and biologics, positively influencing the market's growth. Additionally, different research organizations and market players across the globe are actively investing in developing novel therapies that offer fewer side effects than traditional therapies. They also engage in collaborations by pooling their resources and expertise; the organizations can reduce the time required for drug development and easily address the unmet medical requirements of the patients.

Increasing Prevalence of Rheumatoid Arthritis Boosts Market Demand

The rising cases of rheumatoid arthritis can be attributed to the expansion of the aging population and changing lifestyles. The increasing disease burden is augmenting the global demand for rheumatoid arthritis therapeutics. As per the estimates of Johns Hopkins University & Medicine, rheumatoid arthritis has a prevalence of 1% to 2%, along with a worldwide distribution. The prevalence of the disease is approaching 5% among women who are older than 55. Autoimmune disease is characterized by the inflammation of joint tissue and exhibits deformation of small joints, pain, and swelling in approximately half of the patient population. Additionally, the development and availability of sensitive testing methods allow patients to receive an early diagnosis, further propelling the requirement for rheumatoid arthritis therapeutics. After the detection of the condition, early treatments such as immunosuppressive drug therapy and nonsteroidal anti-inflammatory drugs are initiated. Additionally, women are more susceptible to the disease as the female immune cells produce more inflammatory cytokines, proteins that control immune cell activity and control inflammation.

Investments in Research Activities Support Market Expansion

The increasing emphasis on research activities for addressing the complexities of the disease and the discovery of novel treatments is aiding researchers in developing advanced therapeutic solutions for rheumatoid arthritis and providing lucrative growth opportunities to the market. One of the promising research areas in the disease is the exploration of biological agents that are responsible for targeting unique immune pathways that play a role in inflammation. In July 2024, SetPoint Medical Corporation announced positive topline results for the RESET-RA clinical study. The clinical study evaluates the use of the SetPoint System as a potential neuroimmune modulation treatment for individuals with moderate to severe rheumatoid arthritis who are intolerant to targeted synthetic or biologic disease-modifying anti-rheumatic drugs or incomplete responders. A significant portion of the patient population suffering from rheumatoid arthritis is either intolerant to the approved treatment options available or adequately responding to them. Moreover, the approved immunotherapies also have severe immunosuppressive risks that can result in low treatment adherence, safety concerns, and poor patient satisfaction. Such clinical research studies are expected to augment the development of therapeutic systems that improve treatment outcomes by increasing patient adherence, among others.

Biopharmaceuticals Account for Significant Market Share

The segment's expansion can be attributed to the increasing research studies showcasing the different benefits associated with various biopharmaceuticals. According to an article published in the JAMA Network of the American Medical Association in June 2024, treatment sequences initiated by biosimilar disease-modifying antirheumatic drugs (DMARDs) were shown to be cost-effective in comparison with treatment sequences initiated with leflunomide in patients suffering from rheumatoid arthritis as per a study conducted by a team of researchers from the University of Hong Kong. Such studies highlight the financial feasibility and benefits associated with biosimilar drugs, resulting in their increasing demand.

Additionally, the comparative effectiveness analysis published in the Rheumatology Journal of the Oxford University Press in September 2023 showed that patients who were switched from etanercept originator to biosimilar had similar drug persistence and disease activity as those patients who remained on the originator, thus indicating nonmedical switching does not have a detrimental effect on treatment outcomes. The study was conducted with the help of data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), which tracks patients with rheumatoid arthritis who start targeted or biologic DMARDs.

North America Holds Major Market Share

The expansion of the market in North America can be attributed to the growing prevalence of rheumatoid arthritis in the region, the strong presence of leading market players and research organizations, the rapid growth of the aging population, and the growing emphasis on personalized healthcare. As per the estimates of Johns Hopkins University & Medicine, the average annual incidence of rheumatoid arthritis in the United States is 70 per 100,000 annually. Additionally, the United States Food and Drug Administration (USFDA) is providing approvals for generic drugs for rheumatoid arthritis to increase patient access. In August 2023, Zydus Lifesciences Limited received final approval from the USFDA for manufacturing and marketing their generic suppositories indicated for moderate to severe rheumatoid arthritis. Approval has been given to Zydus for marketing and manufacturing their Indomethacin suppositories at 50 mg strength. Indomethacin suppositories are anti-inflammatory and non-steroidal drugs indicated for rheumatoid arthritis, including moderate to severe ankylosing spondylitis, acute flares of chronic disease, moderate to severe osteoarthritis, acute gouty arthritis, and acute painful shoulder. Additionally, the rising investments from the leading market players in the region towards novel product development and launches and enhancement of their research and development capabilities are further propelling the availability of novel therapeutic solutions in North America, providing lucrative growth opportunities to the rheumatoid arthritis therapeutics market.

Future Market Scenario (2024-2031F)

As per the global rheumatoid arthritis therapeutics market analysis, the market is expected to witness significant growth in the coming years due to the rising cases of rheumatoid arthritis, increasing awareness about the different treatment options, increasing innovation in therapies, and rising shift towards personalized medicines. According to the estimates of an article published in The Lancet of Elsevier Ltd. in October 2023, the number of cases of rheumatoid arthritis is forecasted to increase by 80.2% between 2020 and 2050, and 31.7 million individuals will be living with the disease by 2050 across the globe. Additionally, different healthcare and government organizations are also working on increasing awareness about the impact of treatment adherence and early diagnosis on patients with rheumatoid arthritis.

Moreover, various healthcare organizations are also investing in treatment programs for healthcare professionals to ensure they are updated on the advancements in the treatments for rheumatoid arthritis. Such efforts are expected to bolster the demand for the global rheumatoid arthritis therapeutics market in the coming years. Regulatory bodies, healthcare professionals, and pharmaceutical companies are expected to play a crucial role in allowing for a patient-centric and effective approach to treating rheumatoid arthritis and ensuring the availability of the required therapeutic solutions.

Key Players Landscape and Outlook

Various market players are actively working on increasing the affordability of drugs for treating rheumatoid arthritis and boosting their production. In December 2023, the Institute of Drug Technology (Farmanguinhos/Fiocruz) and Pfizer Inc. signed a technology transfer agreement for producing the generic version of Xeljanz, tofacitinib citrate. The partnership aims to increase the public's access to medications necessary for treating immune-mediated inflammatory diseases, including rheumatoid arthritis, and strengthen national production. Such partnerships are expected to improve the patient population's access to healthcare and pharmaceutical products and services in developing countries.

Additionally, in September 2024, Eva Pharma and Eli Lilly and Company announced that they had entered an agreement to enhance access to baricitinib to patients in low-to-middle-income countries in Africa. Under the agreement, the companies aim to provide 20,000 African patients access to the drug by 2030. Baricitinib is used to treat atopic dermatitis, rheumatoid arthritis, and alopecia areata, among others. The collaboration is also a part of Eli Lilly's 30x30 initiative, which aims to improve access to healthcare facilities for 30 million individuals living in resource-limited areas.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type of Molecule
      • 4.2.1.1. Biopharmaceuticals
        • 4.2.1.1.1. Biologics
        • 4.2.1.1.2. Biosimilars
      • 4.2.1.2. Pharmaceuticals
    • 4.2.2. By Drug Class
      • 4.2.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 4.2.2.2. Corticosteroids
      • 4.2.2.3. Disease-Modifying Antirheumatic Drugs (DMARDs)
      • 4.2.2.4. Janus Kinase (JAK) Inhibitors
      • 4.2.2.5. Biologic Agents
      • 4.2.2.6. Others
    • 4.2.3. By Sales Channel
      • 4.2.3.1. Prescription
      • 4.2.3.2. Over the Counter (OTC)
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type of Molecule
    • 4.3.2. By Drug Class
    • 4.3.3. By Sales Channel
    • 4.3.4. By Region

5. North America Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type of Molecule
      • 5.2.1.1. Biopharmaceuticals
        • 5.2.1.1.1. Biologics
        • 5.2.1.1.2. Biosimilars
      • 5.2.1.2. Pharmaceuticals
    • 5.2.2. By Drug Class
      • 5.2.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.2.2.2. Corticosteroids
      • 5.2.2.3. Disease-Modifying Antirheumatic Drugs (DMARDs)
      • 5.2.2.4. Janus Kinase (JAK) Inhibitors
      • 5.2.2.5. Biologic Agents
      • 5.2.2.6. Others
    • 5.2.3. By Sales Channel
      • 5.2.3.1. Prescription
      • 5.2.3.2. Over the Counter (OTC)
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type of Molecule
          • 5.3.1.2.1.1. Biopharmaceuticals
          • 5.3.1.2.1.1.1. Biologics
          • 5.3.1.2.1.1.2. Biosimilars
          • 5.3.1.2.1.2. Pharmaceuticals
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
          • 5.3.1.2.2.2. Corticosteroids
          • 5.3.1.2.2.3. Disease-Modifying Antirheumatic Drugs (DMARDs)
          • 5.3.1.2.2.4. Janus Kinase (JAK) Inhibitors
          • 5.3.1.2.2.5. Biologic Agents
          • 5.3.1.2.2.6. Others
        • 5.3.1.2.3. By Sales Channel
          • 5.3.1.2.3.1. Prescription
          • 5.3.1.2.3.2. Over the Counter (OTC)
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. AbbVie Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Pfizer Inc.
    • 20.3.3. Bristol Myers Squibb Company
    • 20.3.4. Novartis AG
    • 20.3.5. F. Hoffmann-La Roche Ltd
    • 20.3.6. Amgen Inc.
    • 20.3.7. Bayer AG
    • 20.3.8. Boehringer Ingelheim International GmbH
    • 20.3.9. Eli Lilly and Company
    • 20.3.10. Johnson & Johnson Services, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 3. Global Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 5. Global Rheumatoid Arthritis Therapeutics Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 8. North America Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 9. North America Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 10. North America Rheumatoid Arthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 13. United States Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 14. United States Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 15. Canada Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 17. Canada Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 18. Canada Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 19. Mexico Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 21. Mexico Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 22. Mexico Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 23. Europe Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 25. Europe Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 26. Europe Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 27. Europe Rheumatoid Arthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 30. Germany Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 31. Germany Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 32. France Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 34. France Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 35. France Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 36. Italy Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 38. Italy Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 39. Italy Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 40. United Kingdom Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 42. United Kingdom Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 43. United Kingdom Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 44. Russia Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 46. Russia Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 47. Russia Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 48. Netherlands Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 50. Netherlands Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 51. Netherlands Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 52. Spain Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 54. Spain Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 55. Spain Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 56. Turkey Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 58. Turkey Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 59. Turkey Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 60. Poland Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 62. Poland Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 63. Poland Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 64. South America Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 66. South America Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. South America Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 68. South America Rheumatoid Arthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 71. Brazil Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 72. Brazil Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 73. Argentina Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 75. Argentina Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 76. Argentina Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 77. Asia-Pacific Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 79. Asia-Pacific Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 80. Asia-Pacific Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 81. Asia-Pacific Rheumatoid Arthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 82. India Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 84. India Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. India Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 86. China Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 88. China Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 89. China Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 90. Japan Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 92. Japan Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Japan Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 94. Australia Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 96. Australia Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 97. Australia Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 98. Vietnam Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 100. Vietnam Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 101. Vietnam Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 102. South Korea Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 104. South Korea Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 105. South Korea Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 106. Indonesia Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 108. Indonesia Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 109. Indonesia Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 110. Philippines Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 112. Philippines Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 113. Philippines Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 114. Middle East & Africa Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 116. Middle East & Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 117. Middle East & Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 118. Middle East & Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 121. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 122. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 123. UAE Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 125. UAE Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 126. UAE Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 127. South Africa Rheumatoid Arthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Type of Molecule, 2017-2031F
  • Figure 129. South Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 130. South Africa Rheumatoid Arthritis Therapeutics Market Share (%), By Sales Channel, 2017-2031F
  • Figure 131. By Type of Molecule Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By Sales Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023